Literature DB >> 10739700

Radiation therapy for elderly patient with squamous cell carcinoma of the uterine cervix.

H Sakurai1, N Mitsuhashi, M Takahashi, M Yamakawa, T Akimoto, K Hayakawa, H Niibe.   

Abstract

OBJECTIVE: The purpose of this study was to profile cervical squamous cell carcinoma in elderly patients undergoing radiation therapy and to study the treatment outcome and side effects of therapy.
MATERIALS AND METHODS: A retrospective analysis was carried out from the records of 380 patients with squamous cell carcinoma of the uterine cervix who had been given radiation therapy between 1970 and 1994. The patients were divided into three age groups: under 70 years (youngest group; n = 215), 70 to 79 years (intermediate group; n = 124), and 80 years or older (oldest group; n = 41). Radiation therapy was performed by a combination of external beam therapy and three brachytherapy fractions using low-dose-rate sources.
RESULTS: The 5-year overall survival rates in the youngest, intermediate, and oldest groups were 58, 50, and 33%, respectively, while cause-specific survival rates were 68, 70, and 65%, respectively. For the patients with stage III, the 5-year overall survival rates in the youngest, intermediate, and oldest groups were 59, 48, and 36%, respectively, while cause-specific survival rates were 72, 70, and 70%, respectively. There was no statistical significance in the 5-year intrapelvic recurrence rates among the three groups. Grade 3 or 4 complications occurred in 6.5% of the youngest, 11.3% of the intermediate, and 7.3% of the oldest groups.
CONCLUSION: Radiation therapy with external beam combined with three fractions of low-dose-rate brachytherapy proved both highly effective and safe for senior patients with cervical squamous cell carcinoma. Copyright 2000 Academic Press.

Entities:  

Mesh:

Year:  2000        PMID: 10739700     DOI: 10.1006/gyno.1999.5722

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.

Authors:  Félix Giovanni Delgado; Elizabeth Martínez; María Angélica Céspedes; María Mercedes Bravo; María Cristina Navas; Alba Lucía Cómbita Rojas
Journal:  Immunology       Date:  2008-09-05       Impact factor: 7.397

2.  Impact of age on morbidity and outcome of concurrent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery.

Authors:  Thea Laurentius; Annelore Altendorf-Hofmann; Oumar Camara; Ingo B Runnebaum; Thomas G Wendt
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-15       Impact factor: 4.553

3.  Radiotherapy for Japanese elderly patients with cervical cancer: preliminary survival outcomes and evaluation of treatment-related toxicity.

Authors:  Kenji Yoshida; Ryohei Sasaki; Hideki Nishimura; Daisuke Miyawaki; Tetsuya Kawabe; Yoshiaki Okamoto; Koji Nakabayashi; Shigeki Yoshida; Kazuro Sugimura
Journal:  Arch Gynecol Obstet       Date:  2010-11-30       Impact factor: 2.344

4.  Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: experience from two institutions.

Authors:  Kai-Yun You; Hai-Hua Peng; Yan-Hui Jiang; Zhuo-Fei Bi; Xing-Sheng Qiu
Journal:  Cancer Manag Res       Date:  2019-05-27       Impact factor: 3.989

5.  Evaluating the Incidence Rate of an Accelerated Short Course High Dose Rate Intravaginal Brachytherapy Complications in Patients with Endometrial Cancer.

Authors:  Farnaz Amouzegar Hashemi; Zakieh Vesgari Kiasari; Bita Kalaghchi; Mahdi Aghili; Soraya Gholami; Sepideh Mansouri; Sepand Moalej; Afsaneh Maddah Safaei
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01

6.  Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.

Authors:  Weiping Wang; Xiaorong Hou; Junfang Yan; Jie Shen; Xin Lian; Shuai Sun; Zhikai Liu; Qingyu Meng; Dunhuang Wang; Mei Zhao; Jie Qiu; Ke Hu; Fuquan Zhang
Journal:  BMC Cancer       Date:  2017-08-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.